Clinical trial IJB_3384
A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)(BMT-CTN-2002)
| Organ | Non-Hodgkin lymphoma |
|---|---|
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Xenikos BV |
| EudraCT Identifier | 2021-000343-53 |
| Inclusion criteria | Patients must be at least 18.0 years of age at the time of consent.Patient has undergone first allo-HSCT from any donor source or graft source. Patients diagnosed with Grade III or IV SR-aGVHD after allo-HSCT. SR includes aGVHD initially treated at a lo |
| Last update |